Evidence map›Paper›PMID 21126187›Full record

ReviewAntioxidants & redox signaling2011

Properties and applications of single-chain major histocompatibility complex class I molecules.

Eleni Kotsiou, Joanna Brzostek, Keith G Gould

Abstract readReview
In one paragraph

Review in Antioxidants & redox signaling, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Engineering Cell Lines for Specific Human Leukocyte Antigen Presentation.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eleni KotsiouDepartment of Immunology, Wright-Fleming Institute, Imperial College London, London, England.
Joanna Brzostek
Keith G Gould

Funding

Medical Research Council G0400091Medical Research Council G0400418Wellcome Trust
6 · The paper itself

Abstract

Stable major histocompatibility complex (MHC) class I molecules at the cell surface consist of three separate, noncovalently associated components: the class I heavy chain, the β(2)-microglobulin light chain, and a presented peptide. These three components are assembled inside cells via complex pathways involving many other proteins that have been studied extensively. Correct formation of disulfide bonds in the endoplasmic reticulum is central to this process of MHC class I assembly. For a single specific peptide to be presented at the cell surface for possible immune recognition, between hundreds and thousands of peptide-containing precursor polypeptides are required, so the overall process is relatively inefficient. To increase the efficiency of antigen presentation by MHC class I molecules, and for possible therapeutic purposes, single-chain molecules have been developed in which the three, normally separate components have been joined together via flexible linker sequences in a single polypeptide chain. Remarkably, these single-chain MHC class I molecules fold up correctly, as judged by functional recognition by cells of the immune system, and more recently by X-ray crystallographic structural data. This review focuses on the interesting properties and potential of this new type of engineered MHC class I molecule.

Indexed as

ATP-Binding Cassette Transportersbeta 2-MicroglobulinCD8-Positive T-LymphocytesDisulfidesEndoplasmic ReticulumHistocompatibility Antigens Class IHLA-A2 AntigenHumansPeptidesProtein ConformationProtein EngineeringATP-Binding Cassette Transportersbeta 2-MicroglobulinDisulfidesHistocompatibility Antigens Class IHLA-A2 AntigenPeptidestransporter associated with antigen processing (TAP)

Identifiers

PMID21126187
PMCPMC3125553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.